. Scientific Frontline: Light-Activated Nanoparticles Target Head and Neck Cancer

Friday, November 20, 2026

Light-Activated Nanoparticles Target Head and Neck Cancer

Fluorescence micrographs of head and neck cancer cells declining after light-activated miR-20a-5p nanoparticle therapy.
Image shows cancer cell survival after treatment with an experimental nanoparticle-based therapy carrying a genetic molecule called miR-20a-5p. Researchers at Penn State conducted multiple laboratory tests to measure how many head and neck cancer cells remained alive after exposure to the nanoparticles. In one test in mice bearing tumors grown from human hypopharyngeal (or head and neck) cancer cells, a single dose of the therapy followed by light activation reduced the volume of illuminated tumors by about 95% within 48 hours.
Image Credit: Courtesy Daniel Hayes / Penn State
(CC BY-NC-ND 4.0)

Scientific Frontline: Extended "At a Glance" Summary
: Light-Activated Nanoparticles for Head and Neck Cancer Treatment

The Core Concept: Researchers at Pennsylvania State University (Penn State) developed layered gold-and-silver nanoparticles that deliver a synthetic small regulatory ribonucleic acid (RNA) molecule, microRNA-20a-5p (miR-20a-5p), upon exposure to near-infrared light. In mice bearing tumors grown from human hypopharyngeal cancer cells, a single light-activated dose reduced illuminated tumor volume by approximately 95% within 48 h, whereas non-illuminated tumors continued to grow.

Key Distinction/Mechanism: Systemic administration of genetic cancer therapies such as microRNAs frequently leads to off-target accumulation in healthy organs, including the liver, causing harmful side effects. To achieve precise spatial and temporal control, the gold-and-silver nanoparticles remain inactive until exposed to a specific wavelength of near-infrared light, which the particles convert into localized heat to trigger cargo release exclusively at the illuminated site. Once inside cancer cells, the released miR-20a-5p modulates cellular protein production to disrupt survival pathways and induce cell death.

Origin/History: Biomedical engineer Daniel Hayes began developing light-responsive molecular delivery systems in 2013 to control where therapeutic compounds are released in the body. The research later pivoted toward head and neck oncology through cross-campus collaborations with clinicians and pathologists at Penn State College of Medicine and Penn State Health who recognized its potential to address unmet clinical needs in tissue-sparing tumor treatment.

Major Frameworks/Components:

  • Gold-and-Silver Nanoparticles: Layered metallic nanocarriers engineered to penetrate cancer cells and retain therapeutic cargo until photothermally activated. Exposure to a targeted wavelength of near-infrared light generates localized heat that releases the bound genetic payload on demand.
  • MicroRNA-20a-5p (miR-20a-5p) Payload: A laboratory-synthesized small regulatory RNA molecule that controls cellular protein expression. Within hypopharyngeal cancer cells, this molecule alters biological pathways governing cell survival and death.
  • Photothermal Spatial-Temporal Targeting: A light-triggered release mechanism that confines drug activation to illuminated tumor regions while sparing non-illuminated tissues. This localized approach mitigates the systemic toxicity and liver accumulation that limit conventional genetic therapies.
  • Light Activated Drug Delivery and Release (LADDR) Platform: The commercialization platform managed by Illuminate Therapeutics under a licensing agreement with Penn State. It provides the translational framework required to advance the nanoparticle system through large-scale preclinical safety studies toward clinical evaluation.

Branches of Science: Biomedical Engineering, Biomaterials Science, Molecular Oncology, Oncology.

Future Application: Shrinking head and neck tumors prior to surgery could allow oncologists to excise smaller portions of the tongue, jaw, or face, easing reconstruction and reducing treatment side effects. Illuminate Therapeutics will advance the licensed technology through extensive preclinical safety testing and subsequent human clinical trials to establish safety and efficacy beyond animal models. Beyond head and neck cancers, researchers envision adapting the nanoparticles as a modular delivery platform capable of carrying diverse therapeutic molecules to treat other diseases.

Why It Matters: Invasive treatments for head and neck cancer often impair speaking, swallowing, tasting, and breathing, imposing severe long-term costs on patients' quality of life. Demonstrating that light-controlled microRNA delivery translates from in vitro cell cultures to in vivo tumor regression addresses a persistent barrier to deploying genetic therapeutics safely. By localizing therapeutic activity to illuminated tumors, this strategy establishes an early foundation for organ-preserving cancer treatments with fewer systemic side effects.

Treatments for head and neck cancer often require invasive procedures that can impair a patient’s ability to speak, swallow, and breathe. In a preclinical study using human cancer cells and mouse models, researchers at Pennsylvania State University (Penn State) developed a light-activated nanoparticle system designed to shrink tumors locally while limiting exposure to surrounding healthy tissue.

Published in the Journal of Biomedical Materials Research, the study used nanoparticles composed of layered gold and silver to deliver a synthetic mimic of a small regulatory ribonucleic acid (RNA) molecule called microRNA-20a-5p (miR-20a-5p). MicroRNAs help regulate which proteins cells produce, influencing processes such as cell growth and cell death in a context-dependent manner. The researchers engineered the particles to release their miR-20a-5p cargo only when exposed to near-infrared (NIR) light, providing spatial and temporal control over activation. In mice bearing tumors grown from human hypopharyngeal cancer cells, a specific subtype of head and neck cancer, a single dose followed by light activation reduced illuminated tumor volume by approximately 95% within 48 hours.

“Cancers in the head and neck affect our ability to speak, affect our ability to breathe, affect our ability to swallow, taste, and communicate with society,” said Neerav Goyal, a leader of the research team and a professor in the departments of otolaryngology, neurosurgery, surgery, and public health sciences at Penn State College of Medicine.

For Goyal, who is also a head and neck surgical oncologist for Penn State Health, the potential clinical advantage extends beyond tumor shrinkage. Shrinking tumors prior to surgery could reduce the amount of tongue, jaw, or facial tissue requiring resection, potentially simplifying reconstruction and resulting in fewer treatment-related side effects, he noted.

Targeted Photothermal Delivery

The system was designed to address a persistent limitation in oncology: delivering sufficient therapeutic material to a tumor without damaging healthy organs.

“We really set out to solve a very specific problem,” said Daniel Hayes, a professor of biomedical engineering, the Dorothy Foehr Huck and J. Lloyd Huck Chair in Nanotherapeutics and Regenerative Medicine at Penn State, and the corresponding author of the study.

Hayes explained that administering genetic therapies, such as microRNAs, systemically can lead to accumulation in organs including the liver, raising the risk of harmful side effects.

“Our approach gives you precise control over the delivery of these therapeutics, which would otherwise be difficult to use safely when delivered systemically,” said Hayes, who is also affiliated with Penn State’s Huck Institutes of the Life Sciences and the Materials Research Institute.

To trigger release, the team exposed the nanoparticles to a specific wavelength of NIR light. The metallic particles converted the light into localized heat, releasing the bound miR-20a-5p at the illuminated site. Because NIR light has limited penetration depth in biological tissue, photothermal release is primarily suited to accessible or superficial tumor sites. Additional detail from the primary study—including the exact NIR wavelength, downstream gene targets, and photothermal-only control comparisons—is needed to separate localized heating effects from microRNA-mediated cell death.

The researchers first evaluated the system in human cancer cells grown in the laboratory, testing whether the nanoparticles entered the cells, released their microRNA payload, and altered pathways governing cell survival and death. Following those laboratory experiments, the team tested the nanoparticles in mice carrying tumors developed from human cancer cells. Illuminated tumors shrank substantially, whereas tumors that were not exposed to light continued to grow.

“We had seen similar results in vitro, but seeing that translate to the in vivo environment is really surprising to me,” Hayes said, referring to the shift from cultured cells to living animals.

Preclinical Scope and Next Steps

Despite the preliminary tumor reduction, Hayes emphasized that the technology remains at an early stage of development. Key preclinical parameters—including sample sizes, statistical significance, the route of nanoparticle administration, off-target metal clearance and biodistribution, and tumor recurrence beyond 48 hours—will also need to be evaluated as the work advances.

“Animal models do not translate directly to humans, and so there will be more research and clinical trials before we can really demonstrate that this technology is safe for humans,” Hayes said.

Hayes began developing light-responsive delivery systems in 2013 to control where therapeutic molecules are released in the body. The focus on head and neck oncology emerged later through discussions with Penn State College of Medicine and Penn State Health clinicians and researchers—including Goyal and Douglas Stairs, an associate professor of pathology and laboratory medicine and of neuroscience and experimental therapeutics—who identified the clinical need for localized, tissue-sparing tumor reduction.

Advancing the system toward clinical evaluation will require additional preclinical safety studies and specialized resources. Penn State has licensed the technology to Illuminate Therapeutics for preclinical development.

“It wouldn’t be practical for my lab to do large-scale preclinical and, hopefully, eventually clinical work,” Hayes explained.

Beyond head and neck cancer, the researchers view the nanoparticles as a potential delivery platform that could be adapted to carry different therapeutic molecules for other diseases.

“For now, the findings represent an early step toward a treatment approach that could localize where cancer therapies act,” Goyal said.

Funding: The research was supported by the US National Science Foundation under award number 2033673.

Published in journal: Journal of Biomedical Materials Research

Title: Photo-Activated microRNA 20a Delivery via Core-Shell-Shell Nanoparticles for the Suppression of Head and Neck Cancer

Authors: Angelica M. Helton, Tyus J. Yeingst, Lindsay P. Stone, Dylan P. Kearse, Neerav Goyal, Douglas B. Stairs, and Daniel J. Hayes

Source/Credit: Pennsylvania State University | Richard González

Edited by: Scientific Frontline

Reference Number: bmed112026_01

Privacy Policy | Terms of Service | Contact Us